Crohn's Disease Therapeutics Market Size & Outlook, 2025-2033

Crohn's Disease Therapeutics Market Size

The global crohn's disease therapeutics market size was valued at USD 4.25 Billion in 2024 and is expected  to grow from USD 4.34 Billion in 2025 to reach USD 5.13 Billion by 2033, exhibiting a CAGR of 2.1% during the forecast period (2025–2033). North America is anticipated to grow at a compound annual growth rate (CAGR) of 10.50% during the projected period, making it the largest stakeholder in the global market.

Because people who have Crohn's Disease are more likely to acquire colon cancer, surgical treatments are often used to treat ulcerative colitis in addition to Crohn's Disease in order to lower the risk of cancer. But the hazards connected to gastrointestinal procedures, like infection, marginal ulceration, malabsorption, and strictures, might prevent surgery from being widely used as a treatment for IBD.

Inflammation on the inner lining of the small and large intestines is caused by abnormal immune system responses in Crohn's Disease, a chronic inflammatory bowel disease (IBD) also called regional enteritis. In the Crohn's Disease therapeutics market four primary forms of Crohn's Disease are ileocolitis, ileitis, gastroduodenal, and jejunoileitis. Ileocolitis is an inflammation of the small intestine and a portion of the large intestine, also known as the colon. Ileitis is an inflammation and swelling of the small intestine (ileum). The gastroduodenal syndrome is characterized by inflammation and irritation of the stomach and the upper portion of the small intestine (the duodenum). In jejunoileitis, a patchy area of inflammation develops in the small intestine's upper half (called the jejunum). Crohn's Disease is becoming more common, which has led many businesses to work with regulatory agencies and research groups to develop and release cutting-edge treatments.

To get more insights about this report Download Free Sample Report

Crohn's Disease Therapeutics Market Growth Factors

Growing Adoption of Biologics

Anti-Tumor Necrosis Factor (TNF), anti-interleukin, and anti-integrin antibodies are used as biological treatments for various inflammatory diseases, including Crohn's Disease (CD). These are typically regarded as satisfactory treatments for patients resistant to the effects of steroids and aminosalicylates. However, some patients may stop responding to these treatments, especially anti-TNFs. Developing new therapies for diseases less likely to elicit an immune response is necessary than those currently available. In addition, many new therapeutic classes plan to hit the market over the next few years. Stelara (ustekinumab) was the last biologic approved for Crohn's Disease in 2016. Due to their improved clinical profiles and practical patient dosing, biologics like anti-integrin and interleukin inhibitors are gaining ground in the Crohn's Disease Therapeutics Market.

Successive Launch of New Therapies

Several biologics, including the anti-TNF medications Humira (adalimumab), Remicade (infliximab), and Cimzia (certolizumab pegol), the anti-integrin medications Entyvio (vedolizumab), and Tysabri (natalizumab), and the interleukin (IL) 12 and Risankizuma (rzaa), are already approved for the treatment of moderate-to-severe Crohn's Disease. In addition, the market for treating Crohn's Disease currently has five significant companies with approved branded drugs: Johnson & Johnson (J&J), AbbVie, Takeda, UCB, and Biogen, which are driving the market's growth.

Market Restraining Factors

Failure of Clinical Trials

Most clinical trials being carried out to find a treatment for Crohn's Disease is being terminated, which is expected to hamper the Crohn's Disease therapeutics market growth over the forecast period. For instance, in 2021, Takeda Pharmaceutical Company Limited, a pharmaceutical company, terminated its clinical trial for Ontamalimab (Phase III), which was tested for the treatment of Crohn's Disease. The sponsor's decision to stop funding the SHP647 (Ontamalimab) clinical trial development program for inflammatory bowel diseases caused the trial to end (IBD). Likewise, in 2021, Pfizer Inc. terminated its clinical trial for PF-06687234 (Phase II), which was tested for treating Crohn's Disease. The sponsor changed its R&D priorities and strategy, leading to the trial's termination. Irrespective of Crohn's Disease's severity, corticosteroids are deemed effective in inducing disease remission. However, these drugs fall short of preventing flare-ups.

In addition, side effects related to their long-term use imply that these drugs cannot be used as continuous therapy. Patents of most corticosteroids have already expired in many countries and regions. The growing popularity of generic drugs is projected to instigate more crohn's disease therapeutics industry players to introduce generic versions of branded drugs.

Market Opportunity

High Investment in Research and Development

The market for crohn's disease therapeutics has recently significantly evolved with the introduction of S1P receptor modulators. The current research and development programs in Crohn's Disease are equipped with novel therapies such as Enterome Bio's EB-8018 and Mesoblast's Remostemcel-L. R&D strategies in Crohn's Disease are characterized by an increasing trend towards using S1P modulators combined with other therapeutics for treating moderate-to-severe settings. Major players in the market are developing novel products and spending significantly on research and development, along with major acquisitions and collaborations, to achieve a competitive edge over their counterparts.

Additionally, industry and governments are expected to put a lot of money into R&D capabilities and infrastructure, which will open up lucrative opportunities in the market. The key players are concentrating on implementing organic and inorganic growth strategies to improve their product portfolios. These businesses have also adopted tactics like joint ventures and acquisitions, geographic expansion, investments in R&D, and the creation of novel drugs to compete in the global Crohn's Disease therapeutics market.

Regional Insights

North America is the most significant shareholder in the global market and is expected to grow at a CAGR of 10.50% during the forecast period. The US holds the largest market share. The growth of the Crohn's Disease therapeutics market in the region can be attributed to the presence of key players, increased disease prevalence, and the rising number of health initiatives by private and government firms.

Europe Crohn's Disease Therapeutics Market

Europe is expected to grow at a CAGR of 11.24% during the forecast period. The UK is the most significant region in Europe's market for Crohn's Disease therapeutics. The Crohn's Disease market in the country is projected to witness substantial growth owing to the prevalence of Crohn's Disease patients, key players, and the rise in access to healthcare due to well-established healthcare infrastructure. The growing focus of vendors in R&D to develop novel drugs is further projected to impact the market significantly. The availability of moderate reimbursement coverage and increased healthcare expenditure are other factors influencing the market's growth in the country.

Asia-Pacific Market Trends

Asia-Pacific is expected to grow significantly over the forecast period. Japan is the fastest-growing market for Crohn's Disease therapeutics in Asia-Pacific. Emerging therapies, such as Janus kinase inhibitors and other therapies, are projected to boost the market's growth. The growth of the market in Japan can be attributed to the high prevalence of Crohn's Disease patients, the presence of key players, and increased access to healthcare due to well-established healthcare infrastructure. Several vendors also plan to launch new drugs for Crohn's Disease in the country as it offers significant growth opportunities. For instance, Gilead Pharma has planned to launch Filgotinib in Japan in 2023. Product approvals and licensing agreements will have a positive impact on the growth of the market in Japan.

Drug Class Insights

The TNF-Alpha inhibitors segment is the highest contributor to the market and is expected to grow at a CAGR of 10.29% over the forecast period. Recently approved biologics like Skyrizi (risankizumab-rzaa) are anticipated to dominate the global Crohn's Disease treatment market over the forecast period. Anti-tumor necrosis factor (anti-TNF) therapies, accessible for more than ten years, have historically been the mainstay of the Crohn's Disease market. However, the high proportion of patients who do not respond to treatment has prompted research on novel mechanisms of action (MOAs) in response to recent developments. The introduction of new drugs, the majority of which are anticipated to launch between 2023 and 2025 and target the moderate-to-severe patient population, will be a major factor in the market for Crohn's Disease experiencing significant growth. Due to their improved clinical profiles and practical patient dosing, biologics like anti-integrin and interleukin inhibitors are gaining ground in the Crohn's Disease market.

Gender Type Insights

The Women's segment owns the highest market share and is expected to grow at a CAGR of 10.76% over the forecast period. Due to the slight gender difference between women and men, women were predicted to represent a sizable portion of the global market for crohn's disease therapeutics. Crohn's Disease affects women just as frequently as it affects men, but they may also experience other symptoms that are not always connected to the illness. Women may only experience specific Crohn's symptoms, such as painful or irregular periods and painful sex.

Disease Type Insights

The small/large-intestinal type segment is the highest contributor to the market and is expected to grow at a CAGR of 10.33% during the forecast period. Crohn's Disease affects the intestines, both small and large. It might be broken up into parts, or it might be one long piece. The ileum and the colon are the typical sites of Crohn's Disease inflammation and damage.

Age Group Insights

The 49 yrs. and below segment owns the highest market share and is expected to grow at a CAGR of 10.27% during the forecast period. The onset of Crohn's Disease can occur at any age, but it is most frequently diagnosed in adults and adolescents between the ages of 20 and 30. It could take years for a person to be diagnosed with the disease because the symptoms are similar to those of other gastrointestinal disorders.

List of key players in Crohn's Disease Therapeutics Market

1. AbbVieInc.
2. Biogen
3. Takeda
4. Janssen BiotechInc. (Johnson & Johnson)
5. Bristol-Myers Squibb
6. AstraZeneca
7. Pfizer
8. Red Hill Pharma
9. 4D Pharma

To get more findings about this report Download Market Share

Recent Developments

• December 2022- Pfizer Inc. stated that the U.S. Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) for Etrasimod in patients with moderately-to-severely active ulcerative colitis (UC). The FDA is anticipated to decide in the second half of 2023. In the same patient population, the European Medicines Agency (EMA) has also accepted the Marketing Authorization Application (MAA) for etrasimod, with a decision expected in the first half of 2024.